Epigenetic biomarkers of colorectal cancer: Focus on DNA methylation

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 238-247

  Coppedè, Fabio ^a,b  

^a Department (DAI) of Neuroscience   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Biomarkers; CIMP; Colorectal cancer; DNA methylation; Epigenetics; Folate; One carbon metabolism; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FLUOROURACIL; FOLIC ACID; HOMOCYSTEINE; IRINOTECAN; METHIONINE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P16; PYRIDOXINE; S ADENOSYLMETHIONINE;

ALCOHOL CONSUMPTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; CPG ISLAND; DIET SUPPLEMENTATION; DNA METHYLATION; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MATERNAL NUTRITION; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; RISK REDUCTION; SHORT SURVEY;

EID: 84888203853     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.030     Document Type: Review

References (100)

1. Harrison S., Benziger H. The molecular biology of colorectal carcinoma and its implications: a review. Surgeon 2011, 9:200-210.
2. Migliore L., Migheli F., Spisni R., Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J. Biomed. Biotechnol. 2011, 2011:792362.
3. Gonzalez C.A., Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur. J. Cancer 2010, 46:2555-2562.
4. Hiraoka S., Kato J., Fujiki S., Kaji E., Morikawa T., Murakami T., Nawa T., Kuriyama M., Uraoka T., Ohara N., Yamamoto K. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology 2010, 139:1503-1510.
5. Hoffmeister M., Schmitz S., Karmrodt E., Stegmaier C., Haug U., Arndt V., Brenner H. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin. Gastroenterol. Hepatol. 2010, 8:870-876.
6. Huang L., Wang X., Gong W., Huang Y., Jiang B. The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy based study in southern Chinese. Int. J. Colorectal Dis. 2010, 25:1343-1351.
7. Larsson S.C., Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int. J. Cancer 2006, 119:2657-2664.
8. Bretthauer M. Evidence for colorectal cancer screening. Best Pract. Res. Clin. Gastroenterol. 2010, 24:417-425.
9. Dahm C.C., Keogh R.H., Spencer E.A., Greenwood D.C., Key T.J., Fentiman I.S., Shipley M.J., Brunner E.J., Cade J.E., Burley V.J., Mishra G., Stephen A.M., Kuh D., White I.R., Luben R., Lentjes M.A., Khaw K.T., Rodwell Bingham S.A. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J. Natl. Cancer Inst. 2010, 102:614-626.
10. Hildebrand J.S., Jacobs E.J., Campbell P.T., McCullough M.L., Teras L.R., Thun M.J., Gapstur S.M. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol. Biomar. Prev. 2009, 18:2835-2841.
11. Kim D.H., Smith-Warner S.A., Spiegelman D., Yaun S.S., Colditz G.A., Freudenheim J.L., Giovannucci E., Goldbohm R.A., Graham S., Harnack L., Jacobs E.J., Leitzmann M., Mannisto S., Miller A.B., Potter J.D., Rohan T.E., Schatzkin A., Speizer F.E., Stevens V.L., Stolzenberg-Solomon R., Terry P., Toniolo P., Weijenberg M.P., Willett W.C., Wolk A., Zeleniuch-Jacquotte A., Hunter D.J. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control 2010, 21:1919-1930.
12. Duthie S.J. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J. Inherit. Metab. Dis. 2011, 34:101-109.
13. Coppedè F. The complex relationship between folate/homocysteine metabolism and risk of Down syndrome. Mutat. Res. 2009, 682:54-70.
14. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat. Res. 2001, 475:57-67.
15. Mason J.B. Unraveling the complex relationship between folate and cancer risk. Biofactors 2011, 37:253-260.
16. Kennedy D.A., Stern S.J., Moretti M., Matok I., Sarkar M., Nickel C., Koren G. Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis. Cancer Epidemiol. 2011, 35:2-10.
17. Gibson T.M., Weinstein S.J., Pfeiffer R.M., Hollenbeck A.R., Subar A.F., Schatzkin A., Mayne S.T., Stolzenberg-Solomon R. Pre- and postfortification intake of folate and risk of colorectal cancer in a large prospective cohort study in the United States. Am. J. Clin. Nutr. 2011, 94:1053-1062.
18. Cole B.F., Baron J.A., Sandler R.S., Haile R.W., Ahnen D.J., Bresalier R.S., McKeown-Eyssen G., Summers R.W., Rothstein R.I., Burke C.A., Snover D.C., Church T.R., Allen J.I., Robertson D.J., Beck G.J., Bond J.H., Byers T., Mandel J.S., Mott L.A., Pearson L.H., Barry E.L., Rees J.R., Marcon N., Saibil F., Ueland P.M., Greenberg E.R. Polyp prevention study group, folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007, 297:2351-2359.
19. Ibrahim E.M., Zekri J.M. Folic acid supplementation for the prevention of recurrence of colorectal adenomas: metaanalysis of interventional trials. Med. Oncol. 2010, 27:915-918.
20. Fife J., Raniga S., Hider P.N., Frizelle F.A. Folic acid supplementation and colorectal cancer risk: a meta-analysis. Colorectal Dis. 2011, 13:132-137.
21. Koren G. Folic acid and colorectal cancer: unwarranted fears. Can. Fam. Physician. 2011, 57:889-890.
22. Sie K.K., Medline A., van Weel J., Sohn K.J., Choi S.W., Croxford R., Kim Y.I. Effect of maternal and postweaning folic acid supplementation on colorectal cancer risk in the offspring. Gut 2011, 60:1687-1694.
23. Le Marchand L., White K.K., Nomura A.M., Wilkens L.R., Selhub J.S., Tiirikainen M., Goodman M.T., Murphy S.P., Henderson B.E., Kolonel L.N. Plasma levels of B vitamins and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomar. Prev. 2009, 18:195-201.
24. Le Marchand L., Wang H., Selhub J., Vogt T.M., Yokochi L., Decker R. Association of plasma vitamin B6 with risk of colorectal adenoma in a multiethnic case-control study. Cancer Causes Control 2011, 22:929-936.
25. de Vogel S., Schneede J., Ueland P.M., Vollset S.E., Meyer K., Fredriksen A., Midttun Ø., Bjørge T., Kampman E., Bretthauer M., Hoff G. Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiol. Biomar. Prev. 2011, 20:1726-1735.
26. Taioli E., Garza M.A., Ahn Y.O., Bishop D.T., Bost J., Budai B., Chen K., Gemignani F., Keku T., Lima C.S., Le Marchand L., Matsuo K., Moreno V., Plaschke J., Pufulete M., Thomas S.B., Toffoli G., Wolf C.R., Moore C.G., Little J. Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am. J. Epidemiol. 2009, 170:1207-1221.
27. Zacho J., Yazdanyar S., Bojesen S.E., Tybjærg-Hansen A., Nordestgaard B.G. Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C>T polymorphism and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75, 000 cases and 93, 000 controls. Int. J. Cancer 2011, 128:644-652.
28. Haghighi M.M., Radpour R., Mahmoudi T., Mohebbi S.R., Vahedi M., Zali M.R. Association between MTHFR polymorphism (C677T) with nonfamilial colorectal cancer. Oncol. Res. 2009, 18:57-63.
29. Martìnez-Frìas M.L. The biochemical structure and function of methylenetetrahydrofolate reductase provide the rationale to interpret the epidemiological results on the risk for infants with Down syndrome. Am. J. Med. Genet. A 2008, 146:1477-1482.
30. Eussen S.J., Vollset S.E., Igland J., Meyer K., Fredriksen A., Ueland P.M., Jenab M., Slimani N., Boffetta P., Overvad K., Tjønneland A., Olsen A., Clavel-Chapelon F., Boutron-Ruault M.C., Morois S., Weikert C., Pischon T., Linseisen J., Kaaks R., Trichopoulou A., Zilis D., Katsoulis M., Palli D., Berrino F., Vineis P., Tumino R., Panico S., Peeters P.H., Bueno-de-Mesquita H.B., van Duijnhoven F.J., Gram I.T., Skeie G., Lund E., González C.A., Martínez C., Dorronsoro M., Ardanaz E., Navarro C., Rodríguez L., Van Guelpen B., Palmqvist R., Manjer J., Ericson U., Bingham S., Khaw K.T., Norat T., Riboli E., folate Plasma, variants related genetic Cancer Epidemiol. Biomar. Prev. 2010, 19:1328-1340.
31. Levine A.J., Lee W., Figueiredo J.F., Conti D.V., Vandenberg D.J., Davis B.D., Edlund C.K., Henning S.M., Heber D., Stern M.C., Haile R.W. Variation in folate pathway genes and distal colorectal adenoma risk: a sigmoidoscopy-based case-control study. Cancer Causes Control 2011, 22:541-552.
32. Halsted C.H., Villanueva J.A., Devlin A.M., Chandler C.J. Metabolic interactions of alcohol and folate. J. Nutr. 2002, 132:2367S-2372S.
33. Yamaji T., Iwasaki M., Sasazuki S., Sakamoto H., Yoshida T., Tsugane S. Methionine synthase A2756G polymorphism interacts with alcohol and folate intake to influence the risk of colorectal adenoma. Cancer Epidemiol. Biomar. Prev. 2009, 18:267-274.
34. Hellman A., Chess A. Gene body-specific methylation on the active X chromosome. Science 2007, 315:1141-1143.
35. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 2009, 10:805-811.
36. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74:481-514.
37. Goll M.G., Kirpekar F., Maggert K.A., Yoder J.A., Hsieh C.L., Zhang X., Golic K.G., Jacobsen S.E., Bestor T.H. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006, 311:395-398.
38. Métivier R., Gallais R., Tiffoche C., Le Péron C., Jurkowska R.Z., Carmouche R.P., Ibberson D., Barath P., Demay F., Reid G., Benes V., Jeltsch A., Gannon F., Salbert G. Cyclical DNA methylation of a transcriptionally active promoter. Nature 2008, 452:45-50.
39. Robert M.F., Morin S., Beaulieu N., Gauthier F., Chute I.C., Barsalou A., MacLeod A.R. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. 2003, 33:61-65.
40. Zhu Y.M., Huang Q., Lin J., Hu Y., Chen J., Lai M.D. Expression of human DNA methyltransferase 1 in colorectal cancer tissues and their corresponding distant normal tissues. Int. J. Colorectal Dis. 2007, 22:661-666.
41. Nosho K., Shima K., Irahara N., Kure S., Baba Y., Kirkner G.J., Chen L., Gokhale S., Hazra A., Spiegelman D., Giovannucci E.L., Jaenisch R., Fuchs C.S., Ogino S. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin. Cancer Res. 2009, 15:3663-3671.
42. Ibrahim A.E., Arends M.J., Silva A.L., Wyllie A.H., Greger L., Ito Y., Vowler S.L., Huang T.H., Tavaré S., Murrell A., Brenton J.D. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut 2011, 60:499-508.
43. S. Zhu, H. Zhang, Y. Tang, P. Liu, J. Wang, DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case-control studies, Mol. Biol. Rep., in press.
44. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
45. Feinberg A.P., Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 1983, 111:47-54.
46. Lao V.V., Grady M.W. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:686-700.
47. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96:8681-8686.
48. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Chen X., Ahmed S., Konishi K., Hamilton S.R., Issa J.P. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 2007, 104:18654-18659.
49. T. Hinoue, D.J. Weisenberger, C.P. Lange, H. Shen, H.M. Byun, D. Van Den Berg, S. Malik, F. Pan, H. Noushmehr, C.M. Van Dijk, R.A. Tollenaar, P.W. Laird, Genome-scale analysis of aberrant DNA methylation in colorectal cancer, Genome Res., in press.
50. Yoshimura T., Nagahara M., Kuo C., Turner R.R., Soon-Shiong P., Hoon D.S. Lymphovascular invasion of colorectal cancer is correlated to SPARC expression in the tumor stromal microenvironment. Epigenetics 2011, 6:1001-1011.
51. Lofton-Day C., Model F., Devos T., Tetzner R., Distler J., Schuster M., Song X., Lesche R., Liebenberg V., Ebert M., Molnar B., Grützmann R., Pilarsky C., Sledziewski A. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 2008, 54:414-423.
52. deVos T., Tetzner R., Model F., Weiss G., Schuster M., Distler J., Steiger K.V., Grützmann R., Pilarsky C., Habermann J.K., Fleshner P.R., Oubre B.M., Day R., Sledziewski A.Z., Lofton-Day C. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 2009, 55:1337-1346.
53. Grützmann R., Molnar B., Pilarsky C., Habermann J.K., Schlag P.M., Saeger H.D., Miehlke S., Stolz T., Model F., Roblick U.J., Bruch H.P., Koch R., Liebenberg V., Devos T., Song X., Day R.H., Sledziewski A.Z., Lofton-Day C. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008, 3:e3759.
54. Tänzer M., Balluff B., Distler J., Hale K., Leodolter A., Röcken C., Molnar B., Schmid R., Lofton-Day C., Schuster T., Ebert M.P. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010, 5:e9061.
55. Kostin P.A., Zakharzhevskaia N.B., Generozov E.V., Govorun V.M., Chernyshov S.V., Shchelygin I.A. Hypermethylation of the CDH1, SEPT9, HLTF and ALX4 genes and their diagnostic significance in colorectal cancer. Vopr. Onkol. 2010, 56:162-168.
56. Itzkowitz S., Brand R., Jandorf L., Durkee K., Millholland J., Rabeneck L., Schroy P.C., Sontag S., Johnson D., Markowitz S., Paszat L., Berger B.M. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 2008, 103:2862-2870.
57. Bouzourene H., Hutter P., Losi L., Martin P., Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam. Cancer 2010, 9:167-172.
58. Kamimae S., Yamamoto E., Yamano H.O., Nojima M., Suzuki H., Ashida M., Hatahira T., Sato A., Kimura T., Yoshikawa K., Harada T., Hayashi S., Takamaru H., Maruyama R., Kai M., Nishiwaki M., Sugai T., Sasaki Y., Tokino T., Shinomura Y., Imai K., Toyota M. Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. Cancer Prev. Res. (Phila) 2011, 4:674-683.
59. Yi J.M., Dhir M., Van Neste L., Downing S.R., Jeschke J., Glöckner S.C., de Freitas Calmon M., Hooker C.M., Funes J.M., Boshoff C., Smits K.M., van Engeland M., Weijenberg M.P., Iacobuzio-Donahue C.A., Herman J.G., Schuebel K.E., Baylin S.B., Ahuja N. Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin. Cancer Res. 2011, 17:1535-1545.
60. Baba Y., Nosho K., Shima K., Huttenhower C., Tanaka N., Hazra A., Giovannucci E.L., Fuchs C.S., Ogino S. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology 2010, 139:1855-1864.
61. Crea F., Nobili S., Paolicchi E., Perrone G., Napoli C., Landini I., Danesi R., Mini E. Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist. Updat. 2011, 14:280-296.
62. Cheetham S., Tang M.J., Mesak F., Kennecke H., Owen D., Tai I.T. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br. J. Cancer 2008, 98:1810-1819.
63. Min B.H., Bae J.M., Lee E.J., Yu H.S., Kim Y.H., Chang D.K., Kim H.C., Park C.K., Lee S.H., Kim K.M., Kang G.H. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 2011, 10:344.
64. Van Rijnsoever M., Elsaleh H., Joseph D., McCaul K., Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003, 9:2898-2903.
65. Jover R., Nguyen T.P., Pérez-Carbonell L., Zapater P., Payá A., Alenda C., Rojas E., Cubiella J., Balaguer F., Morillas J.D., Clofent J., Bujanda L., Reñé J.M., Bessa X., Xicola R.M., Nicolás-Pérez D., Castells A., Andreu M., Llor X., Boland C.R., Goel A. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011, 140:1174-1181.
66. *28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J. Chemother. 2008, 20:158-165.
67. Cravo M., Fidalgo P., Pereira A.D., Gouveia-Oliveira A., Chaves P., Selhub J., Mason J.B., Mira F.C., Leitao C.N. DNA methylation as an intermediate biomarker in colorectal cancer: modulation by folic acid supplementation. Eur. J. Cancer Prev. 1994, 3:473-479.
68. van Engeland M., Weijenberg M.P., Roemen G.M., Brink M., de Bruïne A.P., Goldbohm R.A., van den Brandt P.A., Baylin S.B., de Goeij A.F., Herman J.G. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003, 63:3133-3137.
69. Kim Y.I. Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer?. Cancer Epidemiol. Biomar. Prev. 2004, 13:511-519.
70. Arasaradnam R.P., Commane D.M., Bradburn D., Mathers J.C. A review of dietary factors and its influence on DNA methylation in colorectal carcinogenesis. Epigenetics 2008, 3:193-198.
71. Mokarram P., Naghibalhossaini F., Saberi Firoozi M., Hosseini S.V., Izadpanah A., Salahi H., Malek-Hosseini S.A., Talei A., Mojallal M. Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/vitamin B12 status. World J. Gastroenterol. 2008, 14:3662-3671.
72. de Vogel S., Wouters K.A., Gottschalk R.W., van Schooten F.J., de Goeij A.F., de Bruïne A.P., Goldbohm R.A., van den Brandt P-A., Weijenberg M.P., van Engeland M. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer Epidemiol. Biomar. Prev. 2009, 18:3086-3096.
73. Kim J.W., Park H.M., Choi Y.T., Chong S.Y., Oh D., Kim N.K. Polymorphisms in genes involved in folate metabolism and plasma DNA methylation in colorectal cancer patients. Oncol. Rep. 2011, 25:167-172.
74. Neuhouser M.L., Nijhout H.F., Gregory J.F., Reed M.C., James S.J., Liu A., Shane B., Ulrich C.M. Mathematical modeling predicts the effect of folate deficiency and excess on cancer-related biomarkers. Cancer Epidemiol. Biomar. Prev. 2011, 20:1912-1917.
75. Curtin K., Samowitz W.S., Ulrich C.M., Wolff R.K., Herrick J.S., Caan B.J., Slattery M.L. Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr. Cancer 2011, 63:357-366.
76. Karpinski P., Myszka A., Ramsey D., Misiak B., Gil J., Laczmanska I., Grzebieniak Z., Sebzda T., Smigiel R., Stembalska A., Sasiadek M.N. Polymorphisms in methyl-group metabolism genes and risk of sporadic colorectal cancer with relation to the CpG island methylator phenotype. Cancer Epidemiol. 2010, 34:338-344.
77. Wallace K., Grau M.V., Levine A.J., Shen L., Hamdan R., Chen X., Gui J., Haile R.W., Barry E.L., Ahnen D., McKeown-Eyssen G., Baron J.A., Issa J.P. Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev. Res. (Phila) 2010, 3:1552-1564.
78. de Vogel S., Bongaerts B.W., Wouters K.A., Kester A.D., Schouten L.J., de Goeij A.F., de Bruïne A.P., Goldbohm R.A., van den Brandt P.A., van Engeland M., Weijenberg M.P. Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer. Carcinogenesis 2008, 29:1765-1773.
79. Van Guelpen B., Dahlin A.M., Hultdin J., Eklöf V., Johansson I., Henriksson M.L., Cullman I., Hallmans G., Palmqvist R. One-carbon metabolism and CpG island methylator phenotype status in incident colorectal cancer: a nested case-referent study. Cancer Causes Control. 2010, 21:557-566.
80. Schernhammer E.S., Giovannucci E., Baba Y., Fuchs C.S., Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS One 2011, 6:e21102.
81. Figueiredo J.C., Grau M.V., Wallace K., Levine A.J., Shen L., Hamdan R., Chen X., Bresalier R.S., McKeown-Eyssen G., Haile R.W., Baron J.A., Issa J.P. Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol. Biomar. Prev. 2009, 18:1041-1049.
82. Schernhammer E.S., Giovannucci E., Kawasaki T., Rosner B., Fuchs C.S., Ogino S. Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010, 59:794-799.
83. Mason J.B., Dickstein A., Jacques P.F., Haggarty P., Selhub J., Dallal G., Rosenberg I.H. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol. Biomar. Prev. 2007, 16:1325-1329.
84. Hirsch S., Sanchez H., Albala C., de la Maza M.P., Barrera G., Leiva L., Bunout D. Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur. J. Gastroenterol. Hepatol. 2009, 21:436-439.
85. Cooney C.A., Dave A.A., Wolff G.L. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J. Nutr. 2002, 132:2393S-2400S.
86. Waterland R.A., Jirtle R.L. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol. Cell. Biol. 2003, 23:5293-5300.
87. Waterland R.A., Dolinoy D.C., Lin J.R., Smith C.A., Shi X., Tahiliani K.G. Maternal methyl supplements increase offspring DNA methylation at Axin Fused. Genesis 2006, 44:401-406.
88. Waterland R.A., Lin J.R., Smith C.A., Jirtle R.L. Postweaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus. Hum. Mol. Genet. 2006, 15:705-716.
89. Sie K.K., Chen J., Sohn K.J., Croxford R., Thompson L.U., Kim Y.I. Folic acid supplementation provided in utero and during lactation reduces the number of terminal end buds of the developing mammary glands in the offspring. Cancer Lett. 2009, 280:72-77.
90. Ly A., Lee H., Chen J., Sie K.K., Renlund R., Medline A., Sohn K.J., Croxford R., Thompson L.U., Kim Y.I. Effect of maternal and postweaning folic acid supplementation on mammary tumor risk in the offspring. Cancer Res. 2011, 71:988-997.
91. Yajnik C.S., Deshpande S.S., Jackson A.A., Refsum H., Rao S., Fisher D.J., Bhat D.S., Naik S.S., Coyaji K.J., Joglekar C.V., Joshi N., Lubree H.G., Deshpande V.U., Rege S.S., Fall C.H. Vitamin B12 and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia 2008, 51:29-38.
92. Hughes L.A., Van den Brandt P.A., De Bruine A.P., Wouters K.A., Hulsmans S., Spiertz A., Goldbohm R.A., de Goeij A.F., Herman J.G., Weijenberg M.P., van Engeland M. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One 2009, 4:e7951.
93. Bjørge T., Engeland A., Tverdal A., Smith G.D. Body mass index in adolescence in relation to cause-specific mortality: a follow-up of 230,000 Norwegian adolescents. Am. J. Epidemiol. 2008, 168:30-37.
94. Newberne P.M., Bueche D., Suphiphat V., Schrager T.F., Sahaphong S. The influence of pre- and postnatal caloric intake on colon carcinogenesis. Nutr. Cancer 1990, 13:165-173.
95. Steegers-Theunissen R.P., Obermann-Borst S.A., Kremer D., Lindemans J., Siebel C., Steegers E.A., Slagboom P:E., Heijmans B.T. Periconceptional maternal folic acid use of 400μg per day is related to increased methylation of the IGF2 gene in the very young child. PLoS One 2009, 4:e7845.
96. Simmen F.A., Simmen R.C. European Journal the maternal womb: a novel target for cancer prevention in the era of the obesity pandemic?. Eur. J. Cancer Prev. 2011, 20:539-548.
97. Nugent M., Miller N., Kerin M.J. MicroRNAs in colorectal cancer: function, dysregulation and potential as novel biomarkers. Eur. J. Surg. Oncol. 2011, 37:649-654.
98. van Engeland M., Derks S., Smits K.M., Meijer G.A., Herman J.G. Colorectal cancer epigenetics: complex simplicity. J. Clin. Oncol. 2011, 29:1382-1391.
99. Mariadason J.M. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008, 3:28-37.
100. de Krijger I., Mekenkamp L.J., Punt C.J., Nagtegaal I.D. MicroRNAs in colorectal cancer metastasis. J. Pathol. 2011, 224:438-447.